Business Context and Reporting Period
This Form 8-K Current Report was filed by Dermata Therapeutics, Inc. on June 17, 2022. The Company is a Delaware corporation with its principal executive offices in San Diego, California. Its common stock (DRMA) and warrants (DRMAW) are listed on The Nasdaq Capital Market. The Company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance matter regarding stock listing standards rather than financial performance.
Material Changes
On June 17, 2022, the Company received a written notice from The Nasdaq Stock Market indicating non-compliance with the $1.00 Minimum Bid Price requirement (Nasdaq Listing Rule 5550(a)(2)). This non-compliance is based on the closing bid price of the Company's common stock for the last 30 consecutive business days falling below the $1.00 threshold.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180 calendar days, until December 14, 2022, to regain compliance.
- Path to Compliance: Compliance can be achieved if the bid price closes at or above $1.00 per share for a minimum of ten consecutive business days during the compliance period.
- Alternative Options: If the Company fails to regain compliance within the initial period, it may be eligible for an additional 180-day period if it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
- Delisting Risk: Failure to regain compliance or cure the deficiency may result in delisting from The Nasdaq Capital Market, subject to an appeal process.
- Operational Impact: Management states that the receipt of the Notice does not affect the Company's business, operations, or SEC reporting requirements.
Investor Verification Checklist
- Verify the current closing bid price of DRMA to assess proximity to the $1.00 threshold.
- Monitor Company announcements regarding potential reverse stock splits or other capital structure changes intended to restore compliance.
- Review the Company's cash position and liquidity in recent 10-Q or 10-K filings to understand its ability to fund operations while addressing the listing deficiency.
- Check for any subsequent 8-K filings confirming compliance or detailing the outcome of the 180-day period.